Bi-Coastal Pharma International LLC

Generic Supplements, Generic Supplement 2016, 0

Bi-Coastal Pharma International LLC is a privately owned, New Jersey"based generic pharmaceutical marketing company headquartered in Shrewsbury, New Jersey.

Bi-Coastal Pharma International LLC is a privately owned, New Jersey—based generic pharmaceutical marketing company headquartered in Shrewsbury, New Jersey. Led by its President and CEO, Ralph Massa, Jr, Bi-Coastal’s generic product line of prescription and over-the-counter items includes tablets, capsules, liquid, and topical dose–form products that are sold through all major distribution channels in the United States, which include national and regional wholesalers, distributors, chain drugstores, mass merchandisers, GPOs, managed care organizations, and state and government facilities. Bi-Coastal’s management team, which has more than 100 years of combined experience, has expertise in the sales, marketing, manufacturing, regulatory, legal, IT, warehousing, logistics, financial, and consulting aspects of the pharmaceutical industry. Sales efforts of Bi-Coastal’s management team members, over the course of their careers, have generated gross sales in excess of $1 billion. Bi-Coastal’s primary and foremost focus is to continually provide the highest levels of quality and service for the company’s product offerings.

Bi-Coastal values its industry relationships and is continuously expanding its product line from its current long-term, strategic manufacturing partners, as well as consistently fostering new supplier relationships. Bi-Coastal broadens its product offering by contracting with independent laboratories and manufacturers of pharmaceutical products, both foreign and domestic, who benefit from Bi-Coastal’s distribution network and sales and marketing platform. Bi-Coastal obtains marketing rights to pharmaceutical products through distribution, licensing, or acquisition agreements with US and international companies and has launched four ANDAs in 2016, with seven additional ANDAs slated for launch before the close of 2016.

Bi-Coastal’s distribution network includes all classes of trade in the Rx and OTC generic marketplace. Bi-Coastal’s market coverage enables the company to penetrate the US market for the products it markets while maximizing market share. Bi-Coastal’s customer base includes national and regional wholesalers, distributors, chain drug stores, mass merchandisers, GPOs, managed care organizations, and state and government facilities in the United States.

Bi-Coastal’s sales and marketing team attends all major national trade shows and group meetings, including DCAT, ECRM, HDMA, and NACDS. Longstanding industry relationships enable Bi-Coastal to obtain detailed and comprehensive marketing information. Bi-Coastal’s customer network provides channels for marketing campaigns targeted toward consumers, physicians, insurers, hospitals, and pharmacies. Bi-Coastal has a significant pipeline of products to ensure its customers a consistent supply of products for years to come For more information about Bi-Coastal Pharma International LLC, please visit bicoastalpharma.com or contact Ralph Massa, Jr, President and CEO, at 732-530-3900 or at rmassa@bicoastalpharm.com.

For more information, visit http://www.bicoastalpharma.com.